It's just that over the years I have seen examples of serious anticipatory selling ahead of what turned out to be a very positive trial result, and just the opposite, heavy buying ahead of a very negative result report.
In this case, I think the negatives resulting from the one-year delay in the oxypatch and the removal of POH from the ASX 300 are acting as an overall depressant - one which I hope will be dispelled by an oxymorphone performance that falls right into line with expectations, demonstrating that the company has the technology locked down.
POH Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
